These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10754944)

  • 1. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection.
    Patel R; Tyring S; Strand A; Price MJ; Grant DM
    Sex Transm Infect; 1999 Dec; 75(6):398-402. PubMed ID: 10754944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
    Handsfield HH; Warren T; Werner M; Phillips JA
    Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
    Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
    Fife KH; Warren TJ; Justus SE; Heitman CK;
    Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.
    Patel R; Bodsworth NJ; Woolley P; Peters B; Vejlsgaard G; Saari S; Gibb A; Robinson J
    Genitourin Med; 1997 Apr; 73(2):105-9. PubMed ID: 9215091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study.
    Romanowski B; Marina RB; Roberts JN;
    Sex Transm Dis; 2003 Mar; 30(3):226-31. PubMed ID: 12616141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.
    Bodsworth NJ; Crooks RJ; Borelli S; Vejlsgaard G; Paavonen J; Worm AM; Uexkull N; Esmann J; Strand A; Ingamells AJ; Gibb A
    Genitourin Med; 1997 Apr; 73(2):110-6. PubMed ID: 9215092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
    Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
    Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes.
    Baker DA; Blythe JG; Miller JM
    Obstet Gynecol; 1999 Jul; 94(1):103-6. PubMed ID: 10389727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
    Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
    Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
    Warren T; Harris J; Brennan CA
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir.
    Fife KH; Almekinder J; Ofner S
    Sex Transm Dis; 2007 May; 34(5):297-301. PubMed ID: 16960547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group.
    Saiag P; Praindhui D; Chastang C
    J Antimicrob Chemother; 1999 Oct; 44(4):525-31. PubMed ID: 10588314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
    Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
    Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valacyclovir. New indication: for genital herpes, simpler administration.
    Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
    Abudalu M; Tyring S; Koltun W; Bodsworth N; Hamed K
    Clin Infect Dis; 2008 Sep; 47(5):651-8. PubMed ID: 18637755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Faulds D
    Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent genital herpes treatments and their impact on quality of life.
    Brentjens MH; Yeung-Yue KA; Lee PC; Tyring SK
    Pharmacoeconomics; 2003; 21(12):853-63. PubMed ID: 12908841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks.
    Lebrun-Vignes B; Bouzamondo A; Dupuy A; Guillaume JC; Lechat P; Chosidow O
    J Am Acad Dermatol; 2007 Aug; 57(2):238-46. PubMed ID: 17416440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.